MedTrace Logo

Maintaining ERBB Blockade in EGFR-mutated Lung Cancer

NCT02488694 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-01-09

No results posted yet for this study

Summary

This study aims to compare the efficacy of afatinib maintenance with pemetrexed maintenance following induction therapy with platinum/ pemetrexed in patients with metastatic epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC) progressing after first-line treatment with afatinib with respect to progression-free survival.

Conditions

  • Non-small-cell Lung Cancer With Somatic EGFR Mutations

Interventions

DRUG

Afatinib

40 mg/d

DRUG

Pemetrexed

500 mg/m² i.v. on d1 of each 21-day cycle

Sponsors & Collaborators

Principal Investigators

  • Martin Schuler, Prof. Dr. · Westdeutsches Tumorzentrum, Universitätsklinikum Essen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02488694 on ClinicalTrials.gov